Immunological response to quadrivalent HPV vaccine in treatment of recurrent respiratory papillomatosis

Gi, R. E. A. T. P., San Giorgi, M. R. M., Pawlita, M., Michel, A., van Hemel, B. M., Schuuring, E. M. D., Heuvel , van den, E., van der Laan, B. F. A. M. & Dikkers, F. G., Oct-2016, In : European Archives of Oto-Rhino-Laryngology. 273, 10, p. 3231-3236 6 p.

Research output: Contribution to journalArticleAcademicpeer-review

Aim of this study was to explore influence of the quadrivalent HPV vaccine (Gardasil(A (R))) on the immune status of recurrent respiratory papillomatosis (RRP) patients. In retrospective observational study, six RRP patients who received the quadrivalent HPV vaccine and whose HPV seroreactivity was measured were included. Multiplex HPV Serology was used to determine HPV-specific antibodies pre- and post-vaccination. Surgical interventions and patient records were analyzed. Five HPV6 and 1 HPV11 infected patient were included. Mean antibody reactivity against the associated HPV type rose from 1125 median fluorescence intensity (MFI) pre-vaccination to 4690 MFI post-vaccination (p <0.001). Median post-vaccination follow-up was 4 years. Poisson regression analysis showed that the quadrivalent HPV vaccine decreased the incidence rate of surgeries. The immune system of RRP patients is able to increase antibody reactivity against the associated HPV type. A double blind randomized controlled trial is needed to determine whether this immunological increase can cause decrease in number of surgeries.

Original languageEnglish
Pages (from-to)3231-3236
Number of pages6
JournalEuropean Archives of Oto-Rhino-Laryngology
Issue number10
Publication statusPublished - Oct-2016


  • Recurrent respiratory papillomatosis, Vaccine, Therapeutic drug, Immunology, HUMAN-PAPILLOMAVIRUS, RISK-FACTORS, EFFICACY, TYPE-11, CANCER, WOMEN, ONSET, DNA

Download statistics

No data available

ID: 36408846